Abstract: The present invention includes a method of reducing or eliminating a cardiotoxic or cardiopathic effect of one or more active agents comprising: administering to a subject in need thereof an effective amount of one or more lipids that reduce or eliminate the cardiotoxic effect of the one or more active agents, wherein the lipid has formula: R1 and R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds; R3 is R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt; R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, N(R7)2 and COOH; R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, N(R8)2 and COOH; Each R7 is independently H or a C1-C6 branched or unbranched alkyl group; Each R8 is independently H or a C

Abstract: A composition including a salt of 18-MC, wherein the salt is chosen from gentisate, hydrobromide, besylate, napadisylate, hydrochloride, sulfate, oxalate, maleate, mesylate, and tosylate. A composition including a polymorph of 18-MC.

Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.

Abstract: The present invention includes compound having the following structural formula:

Abstract: The present invention includes compound having the following structural formula:

Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.

Abstract: The present invention includes a method of reducing or eliminating a cardiotoxic or cardiopathic effect of one or more active agents comprising: administering to a subject in need thereof an effective amount of one or more lipids that reduce or eliminate the cardiotoxic effect of the one or more active agents, wherein the lipid has formula: .

Abstract: Polymorphic forms of lysergic acid diethyl amide (LSD) in crystalline salt forms. A pharmaceutical formulation of polymorphic forms of LSD in crystalline salt forms including pharmaceutically acceptable excipients. Polymorphic forms of LSD free-base. Polymorphic forms of a salt form of LSD.

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: The present invention includes compound having the following structural formula:

Abstract: The instant invention provides for inositol derivatives, analogs, methods of preparation and uses that inhibit oncogenic signaling pathways and genes. In particular, the compounds disclosed selectively inhibit one or two classes and or isoforms of PI3K. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting KRAS by administering the compound to a patient in need of treatment of cancer.

Abstract: The present invention includes compound having the following structural formula:

Abstract: The present invention includes compound having the following structural formula:

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: The present invention includes compound having the following structural formula:

Abstract: The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.

Abstract: Glyco-amino acids and glycopeptides having three-dimensionally stable configurations are described. These glyco-amino acids and glycopeptides have glycoside functional groups, such as fucose and analogues and derivatives thereof, covalently bound to an amino acid or peptide having a free carboxylic group or sulfate group in an orientation that facilitates the binding between these groups and selectin receptors. The present glyco-amino acids and glycopeptides may be used in the treatment of selectin-mediated disorders, such as inflammation, autoimmune disease and cancer.